Welcome to our dedicated page for Incyte news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte stock.
Incyte Corporation (INCY) is a global biopharmaceutical leader focused on innovative therapies in oncology, dermatology, and immunology. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's clinical developments, regulatory milestones, and strategic initiatives.
Access authoritative information about FDA approvals, clinical trial results, and research collaborations that shape Incyte's pipeline of small-molecule therapies. Our curated collection includes earnings announcements, partnership disclosures, and scientific advancements across therapeutic areas of focus.
Stay informed about developments in blood cancer treatments, autoimmune disorder therapies, and dermatological innovations through verified press releases and objective reporting. This resource serves as your primary source for tracking Incyte's progress in addressing unmet medical needs through targeted therapeutic solutions.
Bookmark this page for streamlined access to critical updates that impact investment decisions and industry understanding. Check regularly for new developments in Incyte's evolving portfolio of proprietary medicines and global healthcare partnerships.
Incyte (Nasdaq:INCY) announced promising 24-week interim data from its Phase 3 STOP-HS clinical trials for povorcitinib, an oral JAK1 inhibitor for hidradenitis suppurativa (HS). The trials demonstrated statistically significant improvements in patients with moderate to severe HS.
Key findings include: Nearly 60% of patients achieved HiSCR50 (≥50% reduction in inflammatory lesions) at Week 24. Additional endpoints showed 31.0%-40.3% achieved HiSCR75, 13.8%-27.7% reached HiSCR90, and 9.2%-21.3% attained HiSCR100. Notably, 62%-70% of patients reported mild or no pain by Week 24.
The data will support regulatory submissions in Europe (2025) and the United States (early 2026). The treatment demonstrated a consistent safety profile with previous data, with both 45mg and 75mg doses well-tolerated.
Incyte (NASDAQ:INCY) will present new data from its dermatology portfolio at the EADV 2025 Congress in Paris from September 17-20. The presentations will highlight key findings from multiple clinical trials, including a late-breaking presentation of 24-week data from the Phase 3 STOP-HS trial of povorcitinib for hidradenitis suppurativa.
The company will showcase results across multiple dermatological conditions, featuring data on povorcitinib (an oral JAK1 inhibitor) and ruxolitinib cream (Opzelura®) (a topical JAK1/2 inhibitor). Presentations will cover treatments for conditions including hidradenitis suppurativa, prurigo nodularis, vitiligo, and atopic dermatitis.
Incyte (Nasdaq:INCY) has launched HS TRUTHS, an educational campaign focused on revealing the realities of living with hidradenitis suppurativa (HS), a chronic inflammatory skin condition. The campaign features authentic stories from HS patients highlighting both physical and emotional impacts of the disease.
HS affects approximately 1% of the population and is characterized by painful nodules and abscesses that can cause permanent tissue damage. The condition significantly impacts patients' daily lives, with diagnosis often taking 7-10 years. A recent survey revealed that 75% of patients experience negative emotions during healthcare discussions.
The initiative aims to improve patient-provider communication and increase understanding of HS's comprehensive impact through unfiltered patient testimonials.
Incyte (Nasdaq: INCY) announced equity inducement awards for Soni Basi, the company's new Executive Vice President and Chief Human Resources Officer. The compensation package includes:
- 29,230 stock options at $84.76 per share, vesting over 4 years
- 6,506 restricted stock units (RSUs), vesting 25% annually over 4 years
- 16,265 target performance shares based on 3-year TSR performance, potentially earning 0-200% of target
The awards were granted under Incyte's 2024 Inducement Stock Incentive Plan and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Incyte (Nasdaq:INCY) has appointed Soni Basi as Executive Vice President and Chief Human Resources Officer (CHRO), effective August 25, 2025. As a key member of the Executive Leadership Team, Basi will lead the company's global HR strategy, focusing on talent acquisition, organizational design, and professional development.
Basi brings over 25 years of experience in global HR and business leadership, previously serving as CHRO at Edelman where she managed 200+ HR professionals. Her prior experience includes leadership roles at AIG, Allergan Pharmaceuticals, The Estée Lauder Companies, and Schering-Plough. She succeeds Paula Swain, who has retired from her position as Executive Vice President and Head of Human Resources.
Incyte (Nasdaq:INCY) has announced its participation in three major healthcare investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference (September 3), Wells Fargo Healthcare Conference (September 4), and Morgan Stanley 23rd Annual Global Healthcare Conference (September 9).
All presentations will be accessible through live webcasts on Investor.Incyte.com and will remain available for replay for 30 days following each event.
Incyte (NASDAQ:INCY) announced that Executive Vice President and Chief Financial Officer Christiana Stamoulis will step down effective September 16, 2025, to pursue another opportunity. Stamoulis, who joined the company in 2019, will assist with the transition period while Incyte searches for her successor.
CEO Bill Meury expressed gratitude for Stamoulis's contributions and emphasized the company's focus on finding a strategic leader to execute their long-term growth plan. Importantly, Incyte reaffirmed its 2025 financial guidance previously announced on July 29, 2025, stating that its financial position and strategic direction remain unchanged.
Incyte (NASDAQ:INCY) reported strong Q2 2025 financial results with total revenues of $1.22 billion, up 16% year-over-year. Key product performance includes Jakafi revenues of $764 million (+8% Y/Y) and Opzelura revenues of $164 million (+35% Y/Y).
The company achieved significant regulatory milestones with FDA approvals for Zynyz in squamous cell anal carcinoma and Monjuvi in follicular lymphoma. Notable pipeline progress includes positive Phase 1 data for INCA033989 in essential thrombocythemia and advancement of multiple Phase 3 programs.
Incyte raised its full-year 2025 guidance for Jakafi to $3.0-3.05 billion (previously $2.95-3.0 billion) and Other Oncology to $500-520 million (previously $415-455 million). The company also announced Bill Meury as new CEO, succeeding retiring Hervé Hoppenot.
Incyte (NASDAQ:INCY) announced it will present initial data from its oncology portfolio at the ESMO Congress 2025 in Berlin, October 17-21. The presentations will feature two key developments: INCA33890, a TGFβR2×PD-1-directed bispecific antibody for advanced solid tumors, and INCB161734, a novel oral inhibitor targeting G12D-mutated KRAS.
The company will deliver an oral presentation on INCB161734's Phase 1 results on October 19, and a mini oral presentation on INCA33890's Phase 1 study on October 17. Additionally, Incyte will present data on retifanlimab combinations for head and neck cancer treatment.
Incyte (Nasdaq:INCY) has scheduled its second quarter 2025 financial results announcement for July 29, 2025. The company will release its Q2 2025 financial results via press release at 7:00 a.m. ET, followed by a conference call and webcast at 8:00 a.m. ET.
The conference call will be accessible through domestic (877-407-3042) and international (201-389-0864) dial-in numbers. A replay will be available for 30 days, and the webcast with slides will be accessible at Investor.Incyte.com for 90 days.
FAQ
What is the current stock price of Incyte (INCY)?
What is the market cap of Incyte (INCY)?
